Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
AssigneeAlkermes, Inc.
InventorBernard Malfroy-Camine
Life of this patent
Estimating the term…
Abstract
The permeability of the blood-brain barrier to endogenous or exogenous neuropharmaceutical or diagnostic agents in an individual's blood stream is increased by administering a bradykinin agonist of blood-brain barrier permeability, such as N-acetyl [Phe.sup.8 (CH.sub.2 -NH)Arg.sup.9 ] bradykinin, to the individual. The bradykinin agonist of blood-brain barrier permeability is co-administered with the agent of interest into a blood vessel such as a vein. This co-administration allows the agent of interest to pass the blood-brain barrier into the brain compartment.
Claims16
A method for increasing the permeability of the blood-brain barrier of a host to a neuropharmaceutical or diagnostic agent comprising co-administering intravenously to said host said agent and an effective amount of a bradykinin agonist of blood-brain barrier permeability;
- said agonist being effective for increasing blood-brain permeability to said agent.
A method for increasing the permeability of the blood-brain barrier of a host to a therapeutically active agent comprising co-administering intravenously to said host said agent and an effective amount of a bradykinin agonist of blood-brain barrier permeability;
- said agonist being effective for increasing blood-brain barrier permeability to said agent.
A method for increasing the permeability of the blood-brain barrier of a human to a therapeutic or prophylactic agent comprising intravenous co-administration to said human of said agent and an effective amount of a bradykinin agonist of blood-brain barrier permeability, said agonist being effective for increasing blood-brain barrier permeability to said agent.
A pharmaceutical composition for intravenous administration to a human for the purpose of increasing the permeability of the blood-brain barrier to a molecule, comprising:
- a) the neuropharmaceutical or diagnostic agent to be delivered from the blood to the brain;
- b) a bradykinin agonist of the blood-brain barrier permeability;
- said agonist being effective for increasing blood-brain barrier permeability to said agent;
- and
- c) a pharmaceutically acceptable carrier.
A method for increasing the permeability of the blood-brain barrier of a host to a neuropharmaceutical or diagnostic agent present in the blood stream of the host comprising administering intravenously to said host an effective amount of a bradykinin agonist of blood-brain barrier permeability under conditions whereby said agent and said agonist are present simultaneously in the blood stream of said host;
- said agonist being effective for increasing blood-brain barrier permeability to said agent.
Dependencies are inferred from the claim text.